Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24555462 | 1.00 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL28769352 | 1.00 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL22964984 | 1.00 | FOLH1 (0.51) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL22965036 | 0.93 | ITGB3 (0.43) | FOLH1ITGB3ITGA2BECE1PREP | |
| SCHEMBL8222427 | 0.89 | FAP (0.42) | ITGB3ITGA2BPREPCASP1 | |
| SCHEMBL2082334 | 0.88 | FOLH1 (0.49) | FOLH1ITGB3ITGA2B | |
| SCHEMBL22965084 | 0.84 | FOLH1 (0.46) | FOLH1ITGB3ITGA2BPREP | |
| SCHEMBL24555463 | 0.84 | PREP (0.48) | PREP | |
| SCHEMBL2084570 | 0.84 | FOLH1 (0.47) | FOLH1ITGB3ITGA2BMMEECE1 | |
| SCHEMBL28943687 | 0.82 | PREP (0.51) | PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370755-B2 | Compositions of trofinetide | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2022-06-28 | — | — | US | disclosed |
| CN-114667136-A | Composition of TROFINETIDE | 诺仁制药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021026066-A1 | COMPOSITIONS OF TROFINETIDE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-02-11 | — | — | WO | disclosed |
| EP-2667715-B1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LTD (NZ) | 2017-07-19 | — | — | EP | disclosed |
| US-9708366-B2 | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LTD. (NZ) | 2017-07-18 | — | — | US | disclosed |
| US-9212204-B2 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-12-15 | — | — | US | disclosed |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-08-13 | — | — | US | disclosed |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-07-16 | — | — | US | disclosed |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2014-05-29 | — | — | US | disclosed |
| US-8637567-B2 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LTD. (NZ) | 2014-01-28 | — | — | US | disclosed |
| EP-2667715-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | Neuren Pharmaceuticals Limited (NZ) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012102832-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2012-08-02 | — | — | WO | disclosed |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-05-12 | — | — | US | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-7714020-B2 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2010-05-11 | — | — | US | disclosed |
| US-7605177-B2 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NL) | 2009-10-20 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | FOLH1 112/4885ITGB3 3942/4885ITGA2B 3791/4885 |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | GRIN2D, GRM2, GRIN2A | FOLH1 872/4885ITGB3 4844/4885ITGA2B 4596/4885 |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | GRIN2D, GRM2, GRIN2A | FOLH1 899/4885ITGB3 4833/4885ITGA2B 4600/4885 |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | FOLH1 172/4885ITGB3 4373/4885ITGA2B 4475/4885 |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | GRIN2D, GRM2, GRIK5 | FOLH1 1124/4885ITGB3 4852/4885ITGA2B 4599/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | FOLH1 83/4885ITGB3 2574/4885ITGA2B 2252/4885 |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | CHAT, GAP43, BDNF | FOLH1 75/4885ITGB3 4744/4885ITGA2B 4469/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | FOLH1 53/4885ITGB3 4594/4885ITGA2B 4356/4885 |
| US-11370755-B2 | Compositions of trofinetide | TXNRD2, BDNF, TTPA | FOLH1 3086/4885ITGB3 3427/4885ITGA2B 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.